138 related articles for article (PubMed ID: 22723311)
1. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
[TBL] [Abstract][Full Text] [Related]
2. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
3. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.
Korse CM; Muller M; Taal BG
Br J Cancer; 2011 Oct; 105(8):1173-5. PubMed ID: 21989216
[TBL] [Abstract][Full Text] [Related]
5. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
6. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
[TBL] [Abstract][Full Text] [Related]
7. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
8. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
9. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Tsukamoto H; Mizoshita T; Sasaki M; Mizushima T; Tanida S; Ozeki K; Hirata Y; Shimura T; Kataoka H; Kamiya T; Nojiri S; Tsukamoto T; Tatematsu M; Joh T
Asian Pac J Cancer Prev; 2011; 12(4):1049-54. PubMed ID: 21790250
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A (CgA)--the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood.
Glinicki P; Jeske W
Endokrynol Pol; 2010; 61(4):384-7. PubMed ID: 20806183
[TBL] [Abstract][Full Text] [Related]
11. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
12. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
[TBL] [Abstract][Full Text] [Related]
13. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
14. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.
Giusti M; Sidoti M; Augeri C; Rabitti C; Minuto F
Eur J Endocrinol; 2004 Mar; 150(3):299-303. PubMed ID: 15012614
[TBL] [Abstract][Full Text] [Related]
15. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].
Kim BW; Lee BI; Kim HK; Cho YS; Chae HS; Lee HK; Kim HJ; Han SW
Korean J Gastroenterol; 2009 Feb; 53(2):84-9. PubMed ID: 19237833
[TBL] [Abstract][Full Text] [Related]
16. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
17. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
18. Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy.
Matsunaga C; Izumi S; Furukubo T; Satoh M; Yamakawa T; Uchida T; Kadowaki D; Hirata S
Clin Nephrol; 2007 Aug; 68(2):93-8. PubMed ID: 17722708
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
Juul-Hansen P; Rydning A
Scand J Gastroenterol; 2011 Apr; 46(4):398-405. PubMed ID: 21142586
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]